Mehryab Fatemeh, Ebrahimi Marzieh, Baharvand Hossein, Haeri Azadeh, Shekari Faezeh
Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Pharm Dev Technol. 2024 Sep;29(7):727-737. doi: 10.1080/10837450.2024.2384448. Epub 2024 Aug 6.
Doxorubicin (DOX) is a chemotherapeutic with considerable efficacy, but its application is limited due to cardiotoxicity. Nanoparticles can improve DOX efficacy and prevent its adverse effects. Herein, DOX-loaded extracellular vesicles (DOX-EVs) were prepared using different loading methods including incubation, electroporation, and sonication in different hydration buffers to permeabilize nanostructures or desalinize DOX for improved entrapment. Different protein:drug (µg:µg) ratios of 1:10, 1:5, and 1:2, and incubation parameters were also investigated. The optimal formulation was characterized by western blotting, electron microscopy, Zetasizer, infrared spectroscopy, and release study. The cellular uptake and efficacy were investigated in MCF-7 spheroids MTS assay, spheroid formation assay (SFA), confocal microscopy, and flow cytometry. The percentage of entrapment efficiency (EE) of formulations was improved from 1.0 ± 0.1 to 22.0 ± 1.4 using a protein:drug ratio of 1:2 and sonication in Tween 80 (0.1%w/v) containing buffer. Characterization studies verified the vesicles' identity, spherical morphology, and controlled drug release properties. Cellular studies revealed the accumulation and cytotoxicity of DOX-EVs in the spheroids, and SFA and confocal microscopy confirmed the efficacy and cellular localization. Flow cytometry results revealed a comparable and amplified efficacy for DOX-EV formulations with different cell origins. Overall, the EV formulation of DOX can be applied as a promising alternative with potential advantages.
阿霉素(DOX)是一种具有显著疗效的化疗药物,但其应用因心脏毒性而受到限制。纳米颗粒可以提高DOX的疗效并预防其不良反应。在此,使用不同的加载方法,包括在不同的水合缓冲液中孵育、电穿孔和超声处理,制备负载DOX的细胞外囊泡(DOX-EVs),以透化纳米结构或使DOX脱盐,从而提高包封率。还研究了1:10、1:5和1:2的不同蛋白质:药物(微克:微克)比例以及孵育参数。通过蛋白质印迹法、电子显微镜、Zetasizer、红外光谱和释放研究对最佳制剂进行了表征。在MCF-7球体中通过MTS测定、球体形成测定(SFA)、共聚焦显微镜和流式细胞术研究了细胞摄取和疗效。使用1:2的蛋白质:药物比例并在含有吐温80(0.1%w/v)的缓冲液中进行超声处理,制剂的包封效率(EE)百分比从1.0±0.1提高到了22.0±1.4。表征研究验证了囊泡的特性、球形形态和可控的药物释放特性。细胞研究揭示了DOX-EVs在球体中的积累和细胞毒性,SFA和共聚焦显微镜证实了其疗效和细胞定位。流式细胞术结果显示,具有不同细胞来源的DOX-EV制剂具有相当且增强的疗效。总体而言,DOX的EV制剂可作为一种有前景的替代物,具有潜在优势。